| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 107.338 | 111.488 | 121.086 | 119.509 | 114.295 | 89.000 | 96.514 | 102.546 | 107.528 | 107.537 |
| Total Income - EUR | 107.338 | 111.766 | 121.086 | 119.509 | 114.295 | 89.574 | 96.514 | 102.546 | 107.730 | 107.629 |
| Total Expenses - EUR | 95.255 | 98.762 | 116.487 | 116.770 | 111.967 | 86.325 | 90.263 | 98.108 | 102.928 | 106.541 |
| Gross Profit/Loss - EUR | 12.083 | 13.004 | 4.599 | 2.739 | 2.328 | 3.249 | 6.250 | 4.438 | 4.801 | 1.089 |
| Net Profit/Loss - EUR | 10.125 | 10.850 | 3.329 | 1.544 | 1.185 | 2.423 | 5.546 | 3.432 | 3.799 | 753 |
| Employees | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
Check the financial reports for the company - Placebo S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 894 | 824 | 5.177 | 4.105 | 3.067 | 2.695 | 1.682 | 856 | 0 | 521 |
| Current Assets | 68.809 | 74.328 | 63.727 | 50.244 | 35.874 | 30.238 | 29.690 | 27.921 | 29.419 | 27.380 |
| Inventories | 66.041 | 71.586 | 61.144 | 46.952 | 33.690 | 27.815 | 26.696 | 25.421 | 27.246 | 24.877 |
| Receivables | 2.450 | 2.155 | 2.106 | 2.361 | 2.130 | 1.364 | 1.439 | 1.717 | 1.805 | 2.061 |
| Cash | 318 | 587 | 477 | 931 | 54 | 1.059 | 1.555 | 783 | 367 | 442 |
| Shareholders Funds | 49.072 | 25.378 | 17.611 | 15.563 | 16.447 | 15.911 | 18.734 | 16.661 | 16.989 | 13.868 |
| Social Capital | 45 | 45 | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | 20.630 | 49.774 | 51.293 | 38.785 | 22.495 | 17.023 | 12.638 | 12.115 | 12.430 | 14.032 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "4619 - 4619" | |||||||||
| CAEN Financial Year |
4619
|
|||||||||
Comments - Placebo S.r.l.